Weiss Multi-Strategy Advisers’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-35,585
Closed -$2.31M 507
2023
Q4
$2.31M Buy
35,585
+2,713
+8% +$163K 0.06% 354
2023
Q3
$2.15M Sell
32,872
-132
-0.4% -$8.3K 0.05% 363
2023
Q2
$1.92M Sell
33,004
-1,996
-6% -$126K 0.04% 475
2023
Q1
$2.16M Buy
35,000
+13,252
+61% +$795K 0.05% 411
2022
Q4
$1.38M Sell
21,748
-3,252
-13% -$236K 0.04% 430
2022
Q3
$1.82M Buy
25,000
+1,540
+7% +$115K 0.05% 418
2022
Q2
$1.59M Buy
23,460
+3,460
+17% +$249K 0.05% 425
2022
Q1
$1.81M Buy
20,000
+1,962
+11% +$161K 0.04% 419
2021
Q4
$1.65M Buy
18,038
+2,538
+16% +$218K 0.04% 414
2021
Q3
$1.26M Buy
15,500
+3,581
+30% +$301K 0.03% 473
2021
Q2
$1.11M Buy
11,919
+427
+4% +$41.4K 0.02% 477
2021
Q1
$1.23M Buy
11,492
+449
+4% +$46.6K 0.03% 462
2020
Q4
$964K Buy
+11,043
New +$780K 0.02% 495

Other funds holding NARI

Weiss Multi-Strategy Advisers's NARI Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Inari Medical, Inc. Common Stock (NARI) in Q1 2024, closing a stake of 35,585 shares — an estimated $2.31M sold.

Weiss Multi-Strategy Advisers first reported a position in NARI in Q4 2020 and held it in 13 quarters. The position peaked at $2.31M in Q4 2023. 231 funds tracked by Wall St. Rank hold NARI as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Inari Medical, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 35,585 Inari Medical, Inc. Common Stock shares in Q1 2024, an estimated $2.31M.
  • Weiss Multi-Strategy Advisers first reported a position in Inari Medical, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Weiss Multi-Strategy Advisers's Inari Medical, Inc. Common Stock position peaked at $2.31M in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.